PTGES3

Prostaglandin E synthase 3 · Q15185 · PTGES3 on Sugi Atlas →

0 patent compounds predicted against PTGES3, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PTGES3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
n-3 Polysaturated Fatty Acids-rich Diet in Psoriasis PHASE4COMPLETED
Type 2 Diabetes Mellitus and Atherosclerosis PHASE4UNKNOWN
Diet Rich in N-3 Polyunsaturated Fatty Acids in Renal Transplant Recipients PHASE4COMPLETED
Go Fish: Omega-3 Fatty Acid Supplementation in Diabetes-Related Kidney Disease PHASE3COMPLETED
European Celecoxib Trial in Primary Breast Cancer PHASE3COMPLETED
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs PHASE3COMPLETED
Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA PHASE2/PHASE3COMPLETED
Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids PHASE2/PHASE3COMPLETED
Addition of Aspirin to Standard of Care in Oral Cancer PHASE2/PHASE3COMPLETED
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite PHASE2/PHASE3WITHDRAWN
Prostanoid Levels After Medication to Prevent Pain Following Third Molar (Wisdom Tooth) Extraction PHASE2COMPLETED
Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention PHASE2COMPLETED
The Effects of Omega-3 Fatty Acids on Aspirin Resistance PHASE1/PHASE2COMPLETED
TRIGLYTZA® VERSUS METFORMIN IN OBESE ADULT TYPE 2 DIABETES (T2DM) PATIENTS OVER 24 WEEKS OF TREATMENT PHASE2NOT_YET_RECRUITING
Omega-3 and Vitamin E Supplementation in Patients With Rheumatoid Arthritis PHASE1COMPLETED
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B nanCOMPLETED
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A nanACTIVE_NOT_RECRUITING
Epithelial Healing and Visual Outcomes Using Omega-3 Therapy Before and After Photorefractive Keratectomy (PRK) Surgery nanCOMPLETED
Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture nanUNKNOWN
Adjunct Use of Diode Laser Therapy and Omega 3 Gel in Local Drug Delivery Approach on The Treatment of Localized Aggressive Periodontitis nanCOMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Anti-Inflammatory Treatment of Schizophrenia nanCOMPLETED
Association and Mechanism Between Cyclooxygenase-2 and Interleukin-6 in Gastric Cancer nanUNKNOWN
Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates nanRECRUITING
Prebiotics and Diet to Reduce Leaky Gut in First Degree Relatives of Crohn's Disease Patients nanCOMPLETED
The Effect of Resolvins on the Resolve of Inflammatory Low Back Pain nanUNKNOWN
Maresin-1 and Resolvin-D1 Levels and Disease Activity in Ulcerative Colitis nanCOMPLETED
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions nanCOMPLETED
Effect of Omega 3 on Oxidative Stress and Nutritional Status of Children on Regular Dialysis nanRECRUITING
Comparison of Docosahexaenoic (DHA) Values in Patients With Polycystic Ovary Syndrome (PCOS) nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTGES3 binder may also engage these)

ProteinNameSimilarity
Q3ZBF7 1.000 Q3ZBF7 →
Q6PWL5 1.000 Q6PWL5 →
Q9R0Q7 1.000 Q9R0Q7 →
G1TGF1 1.000 G1TGF1 →
Q5NVM4 0.999 Q5NVM4 →
P83868 0.997 P83868 →
Q90955 0.994 Q90955 →
COPS2 COP9 signalosome complex subunit 2 0.898 landscape →
TSG101 Tumor susceptibility gene 101 protein 0.897 landscape →
P61203 0.896 P61203 →
B1H1E4 0.896 B1H1E4 →
Q6PFJ9 0.892 Q6PFJ9 →
Q13888 0.891 Q13888 →
Q6IQT4 0.891 Q6IQT4 →
Q9JIB4 0.891 Q9JIB4 →
P61202 0.889 P61202 →
Q9Z2M6 0.889 Q9Z2M6 →
Q5BJT2 0.889 Q5BJT2 →
Q6IR75 0.889 Q6IR75 →
Q32NS4 0.888 Q32NS4 →
Q8BTQ0 0.888 Q8BTQ0 →
Q2TBV5 0.888 Q2TBV5 →
Q6P1K8 0.888 Q6P1K8 →
Q5XIT1 0.887 Q5XIT1 →
Q2TA46 0.887 Q2TA46 →
Q5NVP9 0.887 Q5NVP9 →
A1L167 0.887 A1L167 →
O95164 0.886 O95164 →
Q5TDH0 0.886 Q5TDH0 →
Q3KNV8 0.886 Q3KNV8 →